Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs Redwire Corporation (RDW) Price & Performance

Boston Scientific CorporationTrade
Redwire CorporationTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs Redwire Corporation — how do they compare? Boston Scientific Corporation trades at $51.12 (market cap $71.46B), while Redwire Corporation trades at $13.6 (market cap $3.28B). The key difference: Boston Scientific Corporation is far larger — about 21.8× Redwire Corporation's market cap, and Redwire Corporation is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.

BSXRDW
Market Cap
$71.46B$3.28B
Sector
HealthTechnology
52-Week High
$108.14$25.90
52-Week Low
$42.63$5.06
Enterprise Value
$83.55B$2.81B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.

Redwire Corporation

RDW stock trades at $13.59, up 14.88% in the last 24 hours, reflecting strong momentum after Q2 2026 results. The company reported record revenue of $117.1 million and a growing backlog of $542.1 million, though it remains unprofitable with a net income margin of -57.26%. Technical indicators show a bullish trend, with the current price near the consensus target of $17.50, while analyst sentiment is overwhelmingly positive with 80% buy ratings.

The outlook hinges on execution of its space and defense contracts, but persistent losses and negative cash flows from operations pose significant risks. Upside potential exists if margin improvements materialize, yet investors face volatility from earnings misses and high burn rates.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About Redwire Corporation

Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.

Read more on RDW